Trial Profile

A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Infliximab; Mycophenolate mofetil; Paclitaxel; Pemetrexed; Vinorelbine
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms MDT-BRIDGE
Sponsors AstraZeneca; AstraZeneca AB

08 Oct 2025 Planned primary completion date changed from 1 Apr 2026 to 12 Jan 2026.
04 Mar 2024 Planned End Date changed from 20 Sep 2027 to 27 Aug 2027.
04 Mar 2024 Planned primary completion date changed from 15 Mar 2027 to 1 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com